Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$794,307 Mln
P/E Ratio
75.67
P/B Ratio
55.97
Industry P/E
--
Debt to Equity
2.35
ROE
0.84 %
ROCE
25.23 %
Div. Yield
0.7 %
Book Value
15.86
EPS
11.73
CFO
$53,052.40 Mln
EBITDA
$75,012.70 Mln
Net Profit
$38,462.90 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
| 14.58 | 2.27 | 12.62 | 20.81 | 46.95 | 40.26 | 28.59 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P 100
| -7.84 | -4.23 | -10.10 | 11.63 | 11.27 | 15.45 | 11.18 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
| 32.13 | 59.34 | 32.45 | 63.60 | 28.46 | 13.58 | 36.78 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 186.06 | 329,136.41 | 78.18 | 62.52 | |
| 280.84 | 150,868.66 | 37.2 | 67.55 | |
| 154.58 | 371,930.30 | 17.19 | 29.42 | |
| 82.74 | 208,206.09 | 12.03 | 40.81 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50,... insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Read more
Chairman, CEO & President
Mr. David A. Ricks
Executive VP, General Counsel & Secretary
Ms. Anat Hakim J.D.
Headquarters
Indianapolis, IN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Eli Lilly and Company (LLY) stood at $ 78,715 Mln as on 31-Dec-24
The share price of Eli Lilly and Company (LLY) is $884.54 (NYSE) as of 25-Apr-2025 16:11 EDT. Eli Lilly and Company (LLY) has given a return of 46.95% in the last 3 years.
Eli Lilly and Company (LLY) has a market capitalisation of $ 794,307 Mln as on 25-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/E ratio of Eli Lilly and Company (LLY) is 75.67 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Eli Lilly and Company (LLY) and enter the required number of quantities and click on buy to purchase the shares of Eli Lilly and Company (LLY).
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
The CEO & director of Mr. David A. Ricks. is Eli Lilly and Company (LLY), and CFO & Sr. VP is Ms. Anat Hakim J.D..
There is no promoter pledging in Eli Lilly and Company (LLY).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
38,015
|
|
|
31,320
|
|
|
19,872
|
|
|
14,968
|
| Eli Lilly and Company (LLY) | Ratios |
|---|---|
|
Return on equity(%)
|
84.41
|
|
Operating margin(%)
|
29.88
|
|
Net Margin(%)
|
23.51
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Eli Lilly and Company (LLY) was $10,590 Mln.
$24.81
(
